Back to search results

LITT and Hypofractionated Radiation for Newly Diagnosed Gliomas

This study is looking at a new way to treat newly diagnosed gliomas (a type of brain tumor). It combines two treatments: Laser Interstitial Thermal Therapy (LITT), which uses heat to destroy tumor cells, and Hypofractionated Radiation Therapy, a type of radiation given in fewer, stronger doses. The study wants to see if this combination is safe and effective. Researchers will track any side effects over two years to understand how well the treatment works. You might be able to join if you are 18 or older, have a newly diagnosed high-grade glioma, and your doctors think LITT is a good option for you based on your MRI scans. The study aims to enroll 32 participants, but its current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 32 participants. The specific phase of the study is not specified.
What's involved
You would undergo the LITT procedure, and then have radiation therapy simulation within 10 days of LITT. Radiation treatments would be given once daily, typically five times a week.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events for two years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04699773

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

Recruiting
NAAges 18+InterventionalTreatment
University of Maryland, Baltimore
~32 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:LITTHypofractionated Radiation Therapy

At a glance

Recruiting sites
5 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse Events
Measured over 2 years

Conditions

Glioma
Glioblastoma
Brain Tumor

Explore related trials

GlioblastomaGlioma

Where it's being run

5 sites across 1 states
Maryland5

Who to contact

Mark Mishra, MD
[email protected]
410-328-6080
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

History or presence of serious uncontrolled ventricular or significant arrhythmias.
Any of the following within 6 months prior to registration: myocardial infarction, severe/unstable angina, coronary artery bypass graft, congestive heart failure, cerebrovascular accident, transient ischemic attack , pulmonary embolism 3. Infratentorial tumor or evidence of leptomeningeal spread 4. Inability to undergo a MRI 5. Pregnant or breast-feeding women

What this trial measures

  • Adverse Events2 years

    The ability to complete protocol treatment (i.e. LITT and radiation therapy) without undue treatment-related acute toxicity as defined below: * Safety: \< 40% rate of irreversible Grade 3 or higher neurologic treatment-related toxicity * Early stopping rules: Two or more Grade 2 or higher symptomatic CNS hemorrhages; Eight treatment-related Grade 3 or higher non-hematologic or Grade 4 or higher hematologic treatment related toxicities